Request Demo

Last update 23 Jan 2025

Nimotuzumab

Last update 23 Jan 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

BIOMAb EGFR, CIMAher, Nituzumab

+ [18]

Target

EGFR

Mechanism

EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)

Therapeutic Areas

NeoplasmsNervous System DiseasesDigestive System Disorders+ [5]

Active Indication

Pancreatic CancerSquamous Cell Carcinoma of Head and NeckNasopharyngeal Carcinoma+ [17]

Inactive Indication

AdenocarcinomaAdenosquamous CarcinomaAdvanced Esophageal Squamous Cell Carcinoma+ [17]

Originator Organization

Center For Molecular Immunology

Active Organization

Innogene Kalbiotech Pte Ltd.

Biotech Pharmaceutical Co., Ltd.

Oncoscience GmbH

+ [4]

Inactive Organization

Daiichi Sankyo Co., Ltd.

Eurofarma Laboratórios SA

YM BioSciences, Inc.

+ [2]

Drug Highest PhaseApproved

First Approval Date

IN (11 Sep 2006),

Head and Neck Neoplasms

RegulationOrphan Drug (EU)

Structure/Sequence

Sequence Code 9615890L

Source: *****

Sequence Code 1191632866H

Source: *****

181

Clinical Trials associated with Nimotuzumab

NCT06770452

/ Not yet recruitingPhase 2IIT

A Single-arm Phase II Study of HRS-4642 with Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients with KRAS G12D Mutations

This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.

Start Date01 Feb 2025

Sponsor / Collaborator

Zhejiang University

NCT06781086

/ Not yet recruitingPhase 2

Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with nab-paclitaxel plus gemcitabine (AG) in the perioperative treatment of high-risk resectable/borderline resectable pancreatic cancer.

Start Date20 Jan 2025

Sponsor / Collaborator

Biotech Pharmaceutical Co., Ltd.

[+2]

NCT06773130

/ Not yet recruitingPhase 1/2IIT

An Exploratory Clinical Study of HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

To evaluate the safety and efficacy of HRS-4642 combined with Nimotuzumab in patients with recurrent or metastatic pancreatic ductal adenocarcinoma.

Start Date01 Jan 2025

Sponsor / Collaborator

West China Hospital

100 Clinical Results associated with Nimotuzumab

100 Translational Medicine associated with Nimotuzumab

100 Patents (Medical) associated with Nimotuzumab

442

Literatures (Medical) associated with Nimotuzumab

01 Mar 2025·Neuropsychopharmacology reports

Neurobiology of COVID‐19‐Associated Psychosis/Schizophrenia: Implication of Epidermal Growth Factor Receptor Signaling

Review

Author: Murakami, Masaaki ; Nawa, Hiroyuki

ABSTRACT:

COVID‐19 exhibits not only respiratory symptoms but also neurological/psychiatric symptoms rarely including delirium/psychosis. Pathological studies on COVID‐19 provide evidence that the cytokine storm, in particular (epidermal growth factor) EGF receptor (EGFR, ErbB1, Her1) activation, plays a central role in the progression of viral replication and lung fibrosis. Of note, SARS‐CoV‐2 virus (specifically, S1 spike domain) mimics EGF and directly transactivates EGFR, preceding the inflammatory process. In agreement, the anticancer drugs targeting EGFR such as Nimotuzumab and tyrosine kinase inhibitors are markedly effective on COVID‐19. However, these data might raise a provisional caution regarding implication of psychiatric disorder such as schizophrenia. The author's group has been investigating the etiologic and neuropathologic associations of EGFR signaling with schizophrenia. There are significant molecular associations between schizophrenia and EGFR ligand levels in blood as well as in the brain. In addition, perinatal challenges of EGFR ligands and intraventricular administration of EGF to rodents and monkeys both resulted in severe behavioral and/or electroencephalographic endophenotypes relevant to this disorder. These animal models also display postpubertal abnormality in soliloquy‐like self‐vocalization as well as in intercortical functional connectivity. Here, we discuss neuropsychiatric implication of coronavirus infection and its interaction with the EGFR system, by searching related literatures in PubMed database as of the end of 2023.

01 Feb 2025·INTERNATIONAL IMMUNOPHARMACOLOGY

The inhibitory effects of nimotuzumab on CD276 expression and immune escape in head and neck squamous cell carcinoma: Insights into anticancer mechanisms

Article

Author: Hu, Minwan ; Zhang, Di ; Zhao, Xiuli ; Tang, Borui ; Wang, Xuhong

CD276 has been identified as a novel immune checkpoint, and its overexpression is associated with immune evasion and poor prognosis in various tumors, including head and neck squamous cell carcinoma (HNSCC). Nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, has been approved for various solid tumors. However, it remains unclear whether its anticancer efficacy involves a reduction in CD276 expression. The purpose of this study was to investigate the regulatory effects and potential mechanisms of nimotuzumab on CD276 expression both in vitro and in vivo. In a coculture system, nimotuzumab showed inhibitory effects on TGF-β-induced upregulation of CD276 at both the transcriptional and protein levels in HNSCC cell lines. Mechanistic studies revealed that nimotuzumab primarily suppressed TGF-β-induced CD276 upregulation by blocking EGFR/MEK/ERK, which was further validated by MEK and ERK inhibitors. In xenograft and mice HNSCC models, nimotuzumab exerted antitumor effects accompanied by significantly reduced CD276 expression during tumor progression. Analysis of tumor-infiltrating lymphocytes (TILs) profiles indicated that nimotuzumab orchestrated the tumor immune microenvironment (TIME) by notably increasing the frequency of T lymphocytes, including cytotoxic T lymphocytes and helper T lymphocytes, as well as macrophage cells. However, no significant changes were observed in the populations of NK cells, DC cells, and neutrophils. These findings offer new insights into the anticancer mechanisms of nimotuzumab and its underlying synergy in combined treatments with immunotherapy for HNSCC.

01 Jan 2025·NUCLEAR MEDICINE AND BIOLOGY

225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates

Article

Author: Khaliullina, Daria R ; Libanova, Olga N ; Ermolaev, Stanislav V ; Skasyrskaya, Aino K ; Haliullina, Darya R. ; Lapshina, Elena V ; Vasiliev, Aleksandr N

BACKGROUND:

²¹³Bi is a short-lived radionuclide currently trialed for alpha therapy of various oncological diseases. A serious obstacle to the wide medical use is decay losses of ²¹³Bi during a conventional synthesis of radiopharmaceuticals. In this work, we aimed to develop a two-column ²²⁵Aс/²¹³Bi generator providing the accumulation of ²¹³Bi separately from the parent ²²⁵Ac via continuous circular separation and decay of intermediate ²²¹Fr. When attaining the transient equilibrium, ²¹³Bi could be promptly extracted from the generator with an appropriate complexing agent, including chelator-protein bioconjugates.

METHODS:

Sorption behavior of Bi(III) ions onto the cross-linked dextran gel Sephadex G-25 was studied from solutions of hydrochloric and nitric acid, and from sodium chloride, sodium acetate and DTPA solutions. A bifunctional chelating agent p-SCN-Bn-DTPA was conjugated to an antibody Nimotuzumab specific to the epidermal growth factor receptor, and the procedure of ^207,213Bi-DTPA-Nimotuzumab synthesis in the dextran gel medium was developed. The parameters of ²²⁵Aс/²¹³Bi generator system were evaluated.

RESULTS:

The weight distribution ratios of Bi(III) adsorbed onto the Sephadex G-25 gel were obtained. Up to 85 % of ²¹³Bi was accumulated in the second Sephadex-filled column of ²²⁵Aс/²¹³Bi generator after four-hour circulation of 0.15 M NaCl (pH 5.5) solution. Having passed the solution of DTPA-Nimotuzumab bioconjugate through the second column, a fraction of ²¹³Bi-DTPA-Nimotuzumab radioimmunoconjugate was produced with the radiochemical yield of 64 % ± 3 % (n = 6). High radionuclidic and radiochemical purity of product was achieved.

CONCLUSIONS:

The circulating ²²⁵Aс/²¹³Bi generator provides a ²¹³Bi-labeled bioconjugate as a final product. While a conventional synthesis route including generator milking, bioconjugate labeling and size-exclusion purification takes >20 min, the duration of ²¹³Bi-DTPA-Nimotuzumab production by the method proposed in this work is reduced to 6-8 min.

News (Medical) associated with Nimotuzumab

14 Sep 2022

·www.globenewswire.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent is expected to expire no earlier than February 2039. The allowed claims cover a method of treating a patient diagnosed with glioblastoma or recurrent glioblastoma, wherein the patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents including temozolomide (TMZ), carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), and recombinant oncolytic poliovirus (PVS-RIPO). The allowed claims cover a wide range of doses of MN-166 (ibudilast) as well as the other therapeutic agents. The allowed claims also cover different types of glioblastoma including classical glioblastoma, proneural glioblastoma, mesenchymal glioblastoma, and neural glioblastoma. Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc. commented, “We are very pleased to receive the issue notification for this new patent as it offers additional coverage compared to our other two patents covering glioblastoma. We have an ongoing clinical trial of MN-166 in combination with temozolomide for the treatment of recurrent glioblastoma at the Dana-Farber Cancer Institute, Harvard Medical School. Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone, and this data was presented at the American Society of Clinical Oncology (ASCO) annual meeting. Encouragingly, the FDA granted orphan-drug designation to MN-166 as adjunctive therapy to temozolomide for the treatment of glioblastoma based on this data.” About Glioblastoma According to the American Association of Neurological Surgeons, glioblastoma is an aggressive brain cancer that often results in death during the first 15 months after diagnosis. Glioblastoma develops from glial cells (astrocytes and oligodendrocytes), grows rapidly, and commonly spreads into nearby brain tissue. Glioblastoma is classified as Grade IV, the highest grade, in the World Health Organization (WHO) brain tumor grading system. The American Brain Tumor Association reports that glioblastoma represents about 15% of all primary brain tumors and approximately 10,000 cases of glioblastoma are diagnosed each year in the U.S. Despite decades of advancements in neuroimaging, neurosurgery, chemotherapy and radiation therapy, only modest improvements have been achieved and the prognosis has not improved for individuals diagnosed with glioblastoma. Median survival is about 11-15 months for adults with more aggressive glioblastoma (IDH-wildtype) who receive standard treatment of surgery, temozolomide, and radiation therapy. About MN-166 (ibudilast) MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2021 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT:Geoff O'BrienVice PresidentMediciNova, Inc.info@medicinova.com

Radiation TherapySmall molecular drugASCOCollaborateIPO

10 Apr 2021

·www.globenewswire.com

Zentalis Pharmaceuticals Announces Promising Initial Data

ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated Identified recommended Phase 2 dose for ZN-c3 to be 300 mg QD with continuous dosing Announces plan to start Phase 1/2 osteosarcoma trial in Q3 2021 Company to host webcast event with key opinion leaders on Monday, April 12 at 4:00 p.m. EDT NEW YORK and SAN DIEGO, April 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 1/2 clinical trial of ZN-c3 in patients with advanced solid tumors who are refractory to or ineligible for standard therapy or for whom no standard therapy is available. Initial results showed that monotherapy ZN-c3 use resulted in Exceptional Responses in heavily pre-treated patients in a range of solid tumors, including Partial Responses (PRs) in ovarian cancer, colorectal cancer, non-small cell lung carcinoma and uterine serous carcinoma. Data were reviewed as a late-breaking abstract during the American Association of Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021 and May 17-21, 2021. “The initial clinical data on our WEE1 inhibitor are extremely promising and showcase ZN-c3’s strong potential to improve outcomes in patients with advanced solid tumors who have exhausted available treatment options,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis. “Our WEE1 candidate, which we believe is potentially a best-in-class small molecule, demonstrated favorable safety results with a wide therapeutic window, and resulted in Partial Responses in five patients with a range of cancers. Having identified a recommended dose for future studies, we look forward to advancing clinical trials in a larger number of patients, as well as novel biomarkers that may help select patients who are likely to respond to treatment with ZN-c3. We are looking to make Exceptional Responses commonplace.” Initial Efficacy and Safety Data In the Phase 1 dose-escalation trial, ZN-c3 was dosed starting at 25 mg and going as high as 450 mg QD in patients with advanced or metastatic solid tumors. At the time of the data cutoff on February 12, 2021, 55 patients were evaluated for safety, the primary endpoint. The study remains ongoing and based on the data presented at AACR, ZN-c3 generated 5 Partial Responses. Best Overall Responses: ZN-c3 was generally well-tolerated as a single agent. As of the cutoff date, the most common treatment-related adverse events were mainly Grade 1/2, including nausea (49.0% of patients), diarrhea (32.7% of patients), fatigue (29.0% of patients) and vomiting (29.0% of patients) across all doses. Significant hematological adverse events were limited; treatment-related white blood cell count decrease / neutropenia (7.2% all Grades, 3.6% Grade ≥3), anemia (7.2% all Grades, 5.4% Grade ≥3) and thrombocytopenia (7.2% all Grades, 3.6% Grade ≥3). Results from this study indicate that an oral dose of 300 mg QD with continuous dosing is the recommended Phase 2 dose of ZN-c3 when used as a monotherapy. The 300 mg QD dose demonstrated high plasma exposure levels, while minimizing adverse events. In addition, the pharmacodynamic marker of pCDK1 levels in skin punch biopsies showed active target engagement at relevant pharmacological doses. The Company initiated the Phase 1 expansion portion of the trial with the 300 mg QD dose earlier in 2021 and is exploring this candidate’s potential in combination trials including in ovarian cancer and osteosarcoma. Using this recommended dose, Zentalis will also coordinate with Zentera Therapeutics, Zentalis’ majority-owned joint venture, to initiate a Phase 1b trial investigating ZN-c3 as a single agent in China. “WEE1 is a promising target for cancer therapy, and this dataset provides further validation on the importance of candidates like ZN-c3 that are designed to inhibit the DNA damage checkpoint, resulting in tumor cell death,” said Dr. Anthony Tolcher, CEO, Founder and Director of Clinical Research at NEXT Oncology. “ZN-c3 was shown to be tolerable in this heavily pretreated patient population. Furthermore, this candidate’s early signals of anti-tumor activity are very exciting, and I am even more optimistic that WEE1 inhibition may become an important treatment approach for a wide range of cancers.” KOL Webcast Event: Zentalis will host a webcast event with key opinion leaders Monday, April 12, 2021 at 4:00 p.m. EDT. To register and access the event, the webcast link is available on the Investors & Media section of the Zentalis website at . About ZN-c3 ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1/2 clinical trial in patients with advanced solid tumors and reported initial data from the Phase 1 portion at the AACR Annual Meeting 2021. In addition, the Company is also conducting a Phase 1b trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer, with plans to initiate a Phase 1/2 in combination with chemotherapy in osteosarcoma and a Phase 2 trial investigating ZN-c3 as a monotherapy in patients with uterine serous carcinoma in 2021. About Zentalis Pharmaceuticals Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c5, ZN-c3 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego. For more information, please visit . Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the Unites States and globally, plans and timing for the initiation of and the release of data from our clinical trials and our ability to meet other key milestones, and our participation in upcoming events and presentations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; interim, initial, “topline”, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Investor Contact:Thomas HoffmannSolebury Trout1.646.378.2931thoffmann@soleburytrout.com Media Contact:Julia DeutschSolebury Trout1.646.378.2967jdeutsch@soleburytrout.com

CollaborateAntibodySmall molecular drugAACR

100 Deals associated with Nimotuzumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nimotuzumab	L01XC	DB06192

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pancreatic Cancer	CN	Biotech Pharmaceutical Co., Ltd.	07 Jun 2023
Squamous Cell Carcinoma of Head and Neck	ID	Innogene Kalbiotech Pte Ltd.	19 Oct 2022
Nasopharyngeal Carcinoma	CN	Biotech Pharmaceuticals Pty Ltd	07 Jan 2008
Glioma	UA	Oncoscience AG	10 Oct 2007
Head and Neck Neoplasms	IN	Biocon Biopharmaceuticals Pvt Ltd.	11 Sep 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastrooesophageal junction cancer	Phase 3	CN	Biotech Pharmaceutical Co., Ltd.	01 Aug 2024
Metastatic Colorectal Carcinoma	Phase 3	-	Biotech Pharmaceutical Co., Ltd.	01 Apr 2024
Gastroesophageal junction adenocarcinoma	Phase 3	CN	Biotech Pharmaceutical Co., Ltd.	24 Jul 2023
stomach adenocarcinoma	Phase 3	CN	Biotech Pharmaceutical Co., Ltd.	24 Jul 2023
Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	CN	Biotech Pharmaceutical Co., Ltd.	01 Nov 2021
Cervical Squamous Cell Carcinoma	Phase 3	CN	Biotech Pharmaceutical Co., Ltd.	10 May 2016
Esophageal Squamous Cell Carcinoma	Phase 3	CN	Biotech Pharmaceutical Co., Ltd.	13 Nov 2015
Metastatic Esophageal Squamous Cell Carcinoma	Phase 3	CN	Biotech Pharmaceutical Co., Ltd.	01 Nov 2015
Uterine Cervical Cancer	Phase 3	DZ	-	28 Oct 2015
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck	Phase 3	BR	Eurofarma Laboratórios SA	01 Nov 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_ASIA2024 Manual	Not Applicable	Squamous cell carcinoma of the hypopharynx Neoadjuvant	110	Pembrolizumab combined with TP regimen	adcvnhchyj(ifusucybbz) = ddmbbpojjo ugdohftbnt (ofimzuelgd ) View more	Positive	07 Dec 2024
				Nimotuzumab combined with TP regimen	adcvnhchyj(ifusucybbz) = niglrhscpy ugdohftbnt (ofimzuelgd ) View more
NCT04821778 (Pubmed) Manual	Phase 3	Locally Advanced Esophageal Squamous Cell Carcinoma	64	S-1-Nimotuzumab regimen of radiotherapy	hrvljysbll(syitsqqrqr) = dyeobsleey assbzndojb (holgodtgth, 7.1 - 14.0) View more	Positive	27 Oct 2024
				S-1-Nimotuzumab regimen of radiotherapy (who experienced radical surgery)	hrvljysbll(syitsqqrqr) = cmsbwpnabo assbzndojb (holgodtgth ) View more
WCLC2024 Manual	Not Applicable	Adenocarcinoma of Lung	19	Nimotuzumab plus chemotherapy	ieemvxlqwz(bhnjwtdmjn) = tfxohdqncn kchidlxjhb (napewyccwo, 36.2 - 82.4) View more	Positive	07 Sep 2024
WCLC2024 Manual	Phase 1	Squamous Cell Carcinoma of Head and Neck \| Non-Small Cell Lung Cancer KRAS Mutation	7	NivolumabaNimotuzumab	fgpuxevfps(jzzctejiiq) = xjoatnvakq ftiunhrpjz (vmksuktacy ) View more	Negative	07 Sep 2024
CTRI/2014/09/004980 (ASCO2024) Manual	Phase 3	Locally Advanced Head and Neck Squamous Cell Carcinoma HPV negative	536	Nimotuzumab+radiotherapy+cisplatin	nkgeujckzw(kosuwrmfhu) = qrkqqqfonn perxqvpjih (flkmykopju, 27.6 - 39.4) View more	Positive	02 Jun 2024
				radiotherapy+cisplatin	nkgeujckzw(kosuwrmfhu) = zmdtgslquq perxqvpjih (flkmykopju, 16.7 - 28.8) View more
ASCO2024	Not Applicable	Nasopharyngeal Carcinoma Epstein-Barr virus (EBV) status	242	CCRT+nimotuzumab	kfifixcevn(ymdnbgolmg) = gutkhjzytl gtnqenunnl (bhyjvevvgq ) View more	Positive	24 May 2024
				CCRT alone	kfifixcevn(ymdnbgolmg) = zlieqxlezs gtnqenunnl (bhyjvevvgq ) View more
ASCO2024	Not Applicable	Locally Advanced Cervical Carcinoma EGFR positive	224	Nimotuzumab+CCRT	uhsidfmwpe(emchmsihpy) = jdxndrsgtn knrjntierp (qawisaesod ) View more	Positive	24 May 2024
				CCRT alone	uhsidfmwpe(emchmsihpy) = qfvofublyc knrjntierp (qawisaesod ) View more
ESMO_ASIA2023	Not Applicable	Advanced Nasopharyngeal Carcinoma Epidermal Growth Factor Receptor (EGFR)	-	Nimotuzumab + Chemoradiation	xtgamroumn(wibfuyelrn): HR = 0.56 (95% CI, 0.32 - 0.96), P-Value = 0.0328 View more	Positive	02 Dec 2023
				Nimotuzumab
APACT study (ESMO2023)	Not Applicable	Pancreatic Cancer Adjuvant	795	Adjuvant chemotherapy with nimotuzumab	fkygamlcln(xwbraamuly) = iftkgbmjqw zjuqmhlyiv (xlayhqajyp ) View more	Positive	23 Oct 2023
				Adjuvant chemotherapy without nimotuzumab	fkygamlcln(xwbraamuly) = nbklghliia zjuqmhlyiv (xlayhqajyp ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis